Our primary focus in on creating the "Statin" for the prevention and progression of neurodegenerative diseases
Accuitis has discovered a new class of disease modifying therapeutics, targeting the Restoration of SIRT3 for the treatment of Neurological Disorders:
Alzheimer's Disease/Dementia:
Accuitis has developed AN-018, a new therapy that modifies disease by restoring SIRT3:
- Mitochondrial dysfunction is strongly associated with the pathogenesis of Alzheimer's disease (AD), and recent research has provided further insights into the interplay between SIRT3, mitochondrial function, and neuronal activity in AD. Results indicate that SIRT3 dysfunction leads to mitochondrial and neuronal damage in AD.
- Sirt3 mRNA and protein expression in multiple Brain regions were significantly lower in AD compared to those in cognitively normal subjects. We also identified a strong association between Sirt3 and cognition along with a clear inverse correlation between Sirt3 and tau pathology. These results suggest that Sirt3 could be a new factor involved in the development of Alzheimer's disease.
- Preclinical Studies have demonstrated that AN-018:Inhibits the activity of GSK-3β, a key signaling event implicated in tau hyperphosphorylation. •
- Reduces the Amyloid beta levels (BACE 1 activity & Abeta42) in a dose dependent manner.
- SIRT3 participates in an endogenous neuroprotective response, SIRT3 expression can attenuate AD-related pathological events.
- AN-018 has validated efficacy in multiple in vivo models of AD by activating SIRT3 signaling in the hippocampus and cerebral cortex.
HIV-Associated Neurocognitive Disorder:
AN-018 Demonstrated Efficacy In HIV induced mouse model as a potential first in class therapeutic for the treatment of HIV-Neurocognitive Disorder:
- Mice were evaluated to assess cognitive function by seeing if they could recognize a novel object in a familiar environment Cognitive abnormality seen in HAND mice were significantly reversed by AN-018.
- AN-018 demonstrated efficacy in key HAND Biomarkers Significantly reduced astrogliosis, ameliorated the neuronal abnormalities, and inhibited the activation of monocular phagocytes.
- Systemic Administration Feasible: Readily permeate the blood brain barrier and the blood-cerebrospinal fluid.
- Novel new nano-emulsion targeting intranasal and systemic administration. We are currently performing additional pre-clinical research and IND enabling development activities.
Parkinson's Disease:
AN-018 Demonstrated Efficacy in Parkinsonian Rat model of Parkinson's Disease:
- Prevented loss of motor coordination and • Prevents loss of sensory motor function.
